A Phase 1 interventional study of BI 730460 and Placebo in Healthy, sponsored by Boehringer Ingelheim. Terminated at 1 site in Germany. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-10.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of the single-rising dose (SRD) part (trial part 1) is to investigate the safety and tolerability of BI 730460 in healthy subjects following oral administration of single rising doses. The secondary objective is the exploration of the pharmacokinetics (PK) including dose proportionality, and pharmacodynamics of BI 730460 after single dosing.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
In addition, the following trial-specific exclusion criteria apply:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo tablet(s) matching BI 730460 tablet(s) administered orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.
Drug: Placebo
A single dose of 2 mg BI 730460 administered as film-coated tablets orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.
Drug: BI 730460
A single dose of 8 mg BI 730460 administered as film-coated tablets orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.
Drug: BI 730460
A single dose of 25 mg BI 730460 administered as film-coated tablets orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.
Drug: BI 730460
A single dose of 50 mg BI 730460 administered as film-coated tablets orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.
Drug: BI 730460
A single dose of 100 mg BI 730460 administered as film-coated tablets orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.
Drug: BI 730460
A single dose of 200 mg BI 730460 administered as film-coated tablets orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.
Drug: BI 730460
tablets
tablets
Percentage of Participants With Drug-related Adverse Events
Percentages are calculated using total number of participants per treatment as the denominator. MedDRA version used for reporting: 22.0.
Time frame: From drug administration until end of trial, up to 13 days.
Area Under the Concentration-time Curve of BI 730460 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
Area under the concentration-time curve of BI 730460 in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞).
Time frame: Within 3 hours (h) prior to drug administration followed by 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0, 12.0, 24.0, 34.0, 48.0, 72.0, 96.0, 168.0 hours post drug administration.
Maximum Measured Concentration of BI 730460 in Plasma
Maximum measured concentration of BI 730460 in plasma (Cmax).
Time frame: Within 3 hours (h) prior to drug administration followed by 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0, 12.0, 24.0, 34.0, 48.0, 72.0, 96.0, 168.0 hours post drug administration.
The evaluation of single-rising dose (SRD) of BI 730460 was designed as a partially randomised, single-blind, placebo-controlled trial and the evaluation of bioavailability of BI 730460 with and without food was designed as a randomised, open-label, single-dose, two-way cross-over trial.
| Milestone | Placebo Matching BI 730460 | 2 Milligram (mg) - BI 730460 | 8 mg - BI 730460 | 25 mg - BI 730460 | 50 mg - BI 730460 | 100 mg - BI 730460 | 200 mg - BI 730460 |
|---|---|---|---|---|---|---|---|
| Started | 12 | 6 | 6 | 6 | 6 | 6 | 6 |
| Completed | 12 | 6 | 6 | 6 | 6 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Percentages are calculated using total number of participants per treatment as the denominator. MedDRA version used for reporting: 22.0.
| Percentage of participants (%) | Placebo Matching BI 730460 | 2 Milligram (mg) - BI 730460 | 8 mg - BI 730460 | 25 mg - BI 730460 | 50 mg - BI 730460 | 100 mg - BI 730460 | 200 mg - BI 730460 |
|---|---|---|---|---|---|---|---|
| Percentage of Participants With Drug-related Adverse Events | 8.3 | 0.0 | 0.0 | 16.7 | 0.0 | 0.0 | 0.0 |
Area under the concentration-time curve of BI 730460 in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞).
| Nanomol*hour per litre | 2 Milligram (mg) - BI 730460 | 8 mg - BI 730460 | 25 mg - BI 730460 | 50 mg - BI 730460 | 100 mg - BI 730460 | 200 mg - BI 730460 |
|---|---|---|---|---|---|---|
| Area Under the Concentration-time Curve of BI 730460 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) | 557 ± 35.4 | 2540 ± 41.2 | 5610 ± 25.4 | 11200 ± 56.8 | 31500 ± 23.8 | 47600 ± 36.1 |
Maximum measured concentration of BI 730460 in plasma (Cmax).
| nanomol per litre | 2 Milligram (mg) - BI 730460 | 8 mg - BI 730460 | 25 mg - BI 730460 | 50 mg - BI 730460 | 100 mg - BI 730460 | 200 mg - BI 730460 |
|---|---|---|---|---|---|---|
| Maximum Measured Concentration of BI 730460 in Plasma | 31.8 ± 23.2 | 140 ± 34.0 | 1860 ± 23.8 | 309 ± 11.8 | 597 ± 22.6 | 1470 ± 32.2 |
Collected over Adverse events were collected from drug administration till end of trial, up to 13 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Matching BI 730460 | 0/12 (0%) | 0/12 (0%) | 5/12 (41.7%) |
| 2 Milligram (mg) - BI 730460 | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| 8 mg - BI 730460 | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| 25 mg - BI 730460 | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| 50 mg - BI 730460 | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| 100 mg - BI 730460 | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| 200 mg - BI 730460 | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Total on Treatment | 0/48 (0%) | 0/48 (0%) | 12/48 (25%) |
| Event | Placebo Matching BI 730460 | 2 Milligram (mg) - BI 730460 | 8 mg - BI 730460 | 25 mg - BI 730460 | 50 mg - BI 730460 | 100 mg - BI 730460 | 200 mg - BI 730460 | Total on Treatment |
|---|---|---|---|---|---|---|---|---|
| DyspepsiaGastrointestinal disorders | 0/12 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 1/48 |
| Vessel puncture site haematomaGeneral disorders | 0/12 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 1/48 |
| NasopharyngitisInfections and infestations | 0/12 | 0/6 | 1/6 | 1/6 | 0/6 | 0/6 | 0/6 | 2/48 |
| RhinitisInfections and infestations | 2/12 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 2/48 |
| HeadacheNervous system disorders | 1/12 | 0/6 | 0/6 | 1/6 | 0/6 | 1/6 | 0/6 | 3/48 |
| PresyncopeNervous system disorders | 1/12 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 2/48 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/12 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 1/48 |
| HaematocheziaGastrointestinal disorders | 1/12 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/48 |
| VomitingGastrointestinal disorders | 1/12 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/48 |
| Medical device site reactionGeneral disorders | 1/12 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/48 |
Treated set: Participants who received at least 1 dose of trial drug.
| Age, Continuous(Years) | Placebo Matching BI 730460 | 2 Milligram (mg) - BI 730460 | 8 mg - BI 730460 | 25 mg - BI 730460 | 50 mg - BI 730460 | 100 mg - BI 730460 | 200 mg - BI 730460 | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 33.0 ± 6.8 | 36.0 ± 5.3 | 30.3 ± 6.2 | 30.7 ± 8.5 | 34.7 ± 6.7 | 30.5 ± 4.7 | 33.7 ± 7.9 | 32.7 ± 6.6 |
| Sex: Female, Male(Participants) | Placebo Matching BI 730460 | 2 Milligram (mg) - BI 730460 | 8 mg - BI 730460 | 25 mg - BI 730460 | 50 mg - BI 730460 | 100 mg - BI 730460 | 200 mg - BI 730460 | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 12 | 6 | 6 | 6 | 6 | 6 | 6 | 48 |
| Ethnicity (NIH/OMB)(Participants) | Placebo Matching BI 730460 | 2 Milligram (mg) - BI 730460 | 8 mg - BI 730460 | 25 mg - BI 730460 | 50 mg - BI 730460 | 100 mg - BI 730460 | 200 mg - BI 730460 | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 12 | 6 | 6 | 6 | 6 | 6 | 6 | 48 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo Matching BI 730460 | 2 Milligram (mg) - BI 730460 | 8 mg - BI 730460 | 25 mg - BI 730460 | 50 mg - BI 730460 | 100 mg - BI 730460 | 200 mg - BI 730460 | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 12 | 6 | 6 | 6 | 6 | 6 | 6 | 48 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2018 to primary completion in Mar 2019, 5 months.
Results were first posted in Aug 2022, 3 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.